High-Resolution3DBioprintedLiverConstructs

Why It Matters

Liver disease affects over 1.5 billion people globally, with end-stage liver disease requiring transplants, yet donor organs are critically scarce (over 100,000 on waiting lists in the US alone). Mainstream adoption could lead to on-demand, patient-specific liver tissues for transplantation, ending organ waiting lists and preventing countless deaths. Patients and healthcare systems would be major winners, while the illicit organ trade would be undercut. Significant challenges include achieving sufficient cell density for full organ function, ensuring long-term viability and vascular integration post-implantation, and navigating stringent regulatory approval processes for implantable devices. Commercial availability for therapeutic use is likely 15-20 years away, with companies like United Therapeutics (via its Lung Biotechnology subsidiary) and academic giants in China and the US heavily investing. A second-order consequence could be a redefinition of what constitutes 'organ failure,' potentially expanding the scope of treatable conditions as replacement becomes easier.